Study of new energy-based noninvasive therapies for nonalcoholic fatty liver disease

The incidence and prevalence of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic hepatic steatosis (NAH) remain unknown. It is estimated that 20 to 40% of the Western population is affected by NAFLD. NAFLD is the most common form of chronic liver disease in the world, with an estimated prevalence of approximately 30% in the US. Most cases occur in people aged between 40 and 60 years, but NAFLD is becoming increasingly prevalent in the pediatric population [1]. Although initially it was considered a disease that predominantly affects the female sex, it is currently understood that both sexes are affected equally. It is believed that the prevalence in Hispanics is higher than in whites, while on the other hand, African Americans are less susceptible to the progressive form of the disease and the Asian and Pacific regions are less affected [2]. It is expected to become the main indication for liver transplantation in the future, replacing hepatitis C.